282 related articles for article (PubMed ID: 15515284)
21. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation.
Takigawa C; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
Jpn J Clin Oncol; 2015 Jan; 45(1):67-74. PubMed ID: 25381384
[TBL] [Abstract][Full Text] [Related]
22. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study.
Weinstein SM; Messina J; Xie F
Cancer; 2009 Jun; 115(11):2571-9. PubMed ID: 19373888
[TBL] [Abstract][Full Text] [Related]
23. The role of transdermal fentanyl patches in the effective management of cancer pain.
Gibbs M
Int J Palliat Nurs; 2009 Jul; 15(7):354-9. PubMed ID: 19648851
[TBL] [Abstract][Full Text] [Related]
24. Fentanyl buccal tablet (Fentora) for breakthrough pain.
Med Lett Drugs Ther; 2007 Sep; 49(1270):78-9. PubMed ID: 17878889
[No Abstract] [Full Text] [Related]
25. The role of fentanyl in cancer-related pain.
Prommer E
J Palliat Med; 2009 Oct; 12(10):947-54. PubMed ID: 19807240
[TBL] [Abstract][Full Text] [Related]
26. Integrated strategies for the successful management of breakthrough cancer pain.
Dickman A
Curr Opin Support Palliat Care; 2011 Mar; 5(1):8-14. PubMed ID: 21325998
[TBL] [Abstract][Full Text] [Related]
27. Dynamics of breakthrough pain vs. pharmacokinetics of oral morphine: implications for management.
Zeppetella G
Eur J Cancer Care (Engl); 2009 Jul; 18(4):331-7. PubMed ID: 19473378
[TBL] [Abstract][Full Text] [Related]
28. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
Payne R
Semin Oncol; 1998 Jun; 25(3 Suppl 7):47-53. PubMed ID: 9671331
[TBL] [Abstract][Full Text] [Related]
29. Recent development in therapeutics for breakthrough pain.
Davis MP
Expert Rev Neurother; 2010 May; 10(5):757-73. PubMed ID: 20420495
[TBL] [Abstract][Full Text] [Related]
30. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
31. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain.
Mercadante S; Villari P; Ferrera P; Casuccio A; Mangione S; Intravaia G
Br J Cancer; 2007 Jun; 96(12):1828-33. PubMed ID: 17519902
[TBL] [Abstract][Full Text] [Related]
32. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study.
Fine PG; Messina J; Xie F; Rathmell J
J Pain Symptom Manage; 2010 Nov; 40(5):747-60. PubMed ID: 20594801
[TBL] [Abstract][Full Text] [Related]
33. The treatment of breakthrough pain.
McCarberg BH
Pain Med; 2007; 8 Suppl 1():S8-13. PubMed ID: 17280601
[TBL] [Abstract][Full Text] [Related]
34. A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain.
Farrar JT; Messina J; Xie F; Portenoy RK
Pain Med; 2010 Sep; 11(9):1313-27. PubMed ID: 20807345
[TBL] [Abstract][Full Text] [Related]
35. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L
J Opioid Manag; 2005; 1(1):36-40. PubMed ID: 17315410
[TBL] [Abstract][Full Text] [Related]
36. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain.
Nalamachu S; Hassman D; Wallace MS; Dumble S; Derrick R; Howell J
Curr Med Res Opin; 2011 Mar; 27(3):519-30. PubMed ID: 21208151
[TBL] [Abstract][Full Text] [Related]
37. Breakthrough pain: progress in management.
Lossignol DA; Dumitrescu C
Curr Opin Oncol; 2010 Jul; 22(4):302-6. PubMed ID: 20489619
[TBL] [Abstract][Full Text] [Related]
38. A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials.
Hagen NA; Fisher K; Victorino C; Farrar JT
J Palliat Med; 2007 Feb; 10(1):47-55. PubMed ID: 17298253
[TBL] [Abstract][Full Text] [Related]
39. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ).
Taylor DR; Webster LR; Chun SY; Reinking J; Stegman M; Shoemaker S; Fortner B
Pain Med; 2007 Apr; 8(3):281-8. PubMed ID: 17371416
[TBL] [Abstract][Full Text] [Related]
40. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
